Intellia Therapeutics, Inc. (NTLA): Price and Financial Metrics
GET POWR RATINGS... FREE!
NTLA POWR Grades
- NTLA scores best on the Growth dimension, with a Growth rank ahead of 35.04% of US stocks.
- NTLA's strongest trending metric is Quality; it's been moving up over the last 177 days.
- NTLA's current lowest rank is in the Stability metric (where it is better than 7.88% of US stocks).
NTLA Stock Summary
- INTELLIA THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 10.68% of US listed stocks.
- Of note is the ratio of INTELLIA THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; only 7.45% of US stocks have a lower such ratio.
- With a price/sales ratio of 90.87, INTELLIA THERAPEUTICS INC has a higher such ratio than 97.56% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to INTELLIA THERAPEUTICS INC are XBIT, CRSP, ARCT, CRNX, and FATE.
- NTLA's SEC filings can be seen here. And to visit INTELLIA THERAPEUTICS INC's official web site, go to www.intelliatx.com.
NTLA Valuation Summary
- In comparison to the median Healthcare stock, NTLA's price/sales ratio is 1844.09% higher, now standing at 90.4.
- NTLA's price/sales ratio has moved down 34.9 over the prior 78 months.
Below are key valuation metrics over time for NTLA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NTLA | 2022-09-23 | 90.4 | 4.7 | -10.2 | -10.0 |
| NTLA | 2022-09-22 | 95.7 | 4.9 | -10.8 | -10.6 |
| NTLA | 2022-09-21 | 99.7 | 5.1 | -11.3 | -11.1 |
| NTLA | 2022-09-20 | 104.8 | 5.4 | -11.9 | -11.7 |
| NTLA | 2022-09-19 | 106.4 | 5.5 | -12.0 | -11.9 |
| NTLA | 2022-09-16 | 110.2 | 5.7 | -12.5 | -12.3 |
NTLA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NTLA has a Quality Grade of D, ranking ahead of 18.09% of graded US stocks.
- NTLA's asset turnover comes in at 0.066 -- ranking 302nd of 681 Pharmaceutical Products stocks.
- AGIO, CMRX, and JAZZ are the stocks whose asset turnover ratios are most correlated with NTLA.
The table below shows NTLA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.066 | 1 | -0.397 |
| 2021-03-31 | 0.088 | 1 | -0.420 |
| 2020-12-31 | 0.120 | 1 | -0.510 |
| 2020-09-30 | 0.156 | 1 | -0.586 |
| 2020-06-30 | 0.137 | 1 | -0.536 |
| 2020-03-31 | 0.135 | 1 | -0.414 |
NTLA Price Target
For more insight on analysts targets of NTLA, see our NTLA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $176.19 | Average Broker Recommendation | 1.47 (Moderate Buy) |
NTLA Stock Price Chart Interactive Chart >
NTLA Price/Volume Stats
| Current price | $56.00 | 52-week high | $143.92 |
| Prev. close | $56.03 | 52-week low | $37.08 |
| Day low | $56.00 | Volume | 1,122 |
| Day high | $56.00 | Avg. volume | 1,204,481 |
| 50-day MA | $62.24 | Dividend yield | N/A |
| 200-day MA | $69.75 | Market Cap | 4.26B |
Intellia Therapeutics, Inc. (NTLA) Company Bio
Intellia Therapeutics a gene editing company, develops therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Latest NTLA News From Around the Web
Below are the latest news stories about INTELLIA THERAPEUTICS INC that investors may wish to consider to help them evaluate NTLA as an investment opportunity.
The Top 5 Stocks Cathie Wood Is Buying This WeekCathie Wood announced that she would step down as portfolio manager for PRNT and IZRL. |
Cathie Wood Goes Shopping for Biotech: 3 Stocks She Just BoughtThe founder and CEO of ARK Investment Management is buying up drugmaker stocks like they're going out of style. |
Cathie Wood Is Loading Up on These 3 Stocks: Should You?Warren Buffett famously stated that it's smart to "be fearful when others are greedy and be greedy when others are fearful." All of Wood's ARK Invest exchange-traded funds (ETFs) are down significantly this year. Ginkgo Bioworks specializes in cell programming. |
Intellia Therapeutics (NTLA) Receives a Buy from SVB SecuritiesSVB Securities analyst Mani Foroohar maintained a Buy rating on Intellia Therapeutics (NTLA - Research Report) today and set a price target of $158.00. The company's shares closed last Friday at $65.71.Foroohar covers the Healthcare sector, focusing on stocks such as Moderna, Alnylam Pharma, and Ionis Pharmaceuticals. According to TipRanks, Foroohar has an average return of -12.5% and a 44.62% success rate on recommended stocks. In addition to SVB Securities, Intellia Therapeutics also received a Buy from JMP Securities's Silvan Tuerkcan in a report issued on September 16. However, today, Citigroup maintained a Sell rating on Intellia Therapeutics (NASDAQ: NTLA). |
5 Top Stocks Cathie Wood Is Buying Right NowCathie Wood's ARKK is down over 50% YTD, although the fund manager is still continuing her purchases of high conviction companies. |
NTLA Price Returns
| 1-mo | -5.18% |
| 3-mo | 8.19% |
| 6-mo | -26.44% |
| 1-year | -59.83% |
| 3-year | 319.48% |
| 5-year | 125.35% |
| YTD | -52.64% |
| 2021 | 117.35% |
| 2020 | 270.82% |
| 2019 | 7.47% |
| 2018 | -28.98% |
| 2017 | 46.61% |
Continue Researching NTLA
Want to see what other sources are saying about Intellia Therapeutics Inc's financials and stock price? Try the links below:Intellia Therapeutics Inc (NTLA) Stock Price | Nasdaq
Intellia Therapeutics Inc (NTLA) Stock Quote, History and News - Yahoo Finance
Intellia Therapeutics Inc (NTLA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...